https://www.live-feeds.com/feed/moderna-s-cancer-vaccine-gives-stock-a-new-growth-story-will-it-have-a-happy-endingContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-s-cancer-vaccine-gives-stock-a-new-growth-story-will-it-have-a-happy-endinghttps://www.live-feeds.com/feed/moderna-s-cancer-vaccine-gives-stock-a-new-growth-story-will-it-have-a-happy-ending#u50546Fri, 28 Aug 2026 06:56:06 +0000Moderna and Merck have developed an mRNA vaccine that prevents melanoma from returning. The treatment represents a shift toward viable cancer vaccinations and has triggered a 14% jump in Moderna stock, pushing the price past $150. Wolfe analysts estimate the cancer-vaccine opportunity is worth $9.2 billion. While the breakthrough suggests a potential wave of similar vaccines for other cancers, experts continue to evaluate the barriers to wide clinical use and the long-term efficacy of the treatment.Why it mattersTraditional cancer treatments often struggle with recurrence after primary tumors